<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899154</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03050-55</org_study_id>
    <nct_id>NCT04899154</nct_id>
  </id_info>
  <brief_title>Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy</brief_title>
  <acronym>MEDIBIOTE 3</acronym>
  <official_title>MEDIBIOTE 3: Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Européen Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Européen Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spondyloarthritis (SpA) is a group of inflammatory rheumatic disorders that mainly manifested&#xD;
      by inflammatory pain of the spine, pelvis and sometimes limbs. Classically, SpA has been&#xD;
      classified into several subtypes, such as ankylosing spondylitis (AS), psoriatic arthritis&#xD;
      (PsA), inflammatory bowel disease (IBD)-associated.&#xD;
&#xD;
      Several studies have shown specific changes in the gut microbiota during SpA. A recent,&#xD;
      uncontrolled study suggested that the therapeutic response to anti-TNFα (Tumor Necrosis&#xD;
      Factor) therapy could be predicted by analysis of the gut microbiota.&#xD;
&#xD;
      The purpose of the study MEDIBIOTE 3 is to confirm that in SpA, the composition of the&#xD;
      intestinal microbiota at the initiation of treatment is predictive of the response to&#xD;
      treatment with biotherapy (anti-TNFα / anti-IL17).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variability in the qualitative and quantitative composition of intestinal microbiota in patients responding to biotherapy compared to the group of non-responding patients</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences on intestinal microbiota composition (qualitative and quantitative) of patients with Spa versus healthy controls.</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Patients with spondyloarthritis (Spa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool sampling</intervention_name>
    <description>Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.</description>
    <arm_group_label>Patients with spondyloarthritis (Spa)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool sampling</intervention_name>
    <description>Participants will provide one stool sample at inclusion</description>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For patient with spondyloarthritis:&#xD;
&#xD;
          -  Diagnosed for spondyloarthritis or pure axial or axial type psoriatic rheumatism&#xD;
             according to Assessment of Spondyloarthritis International Society (ASAS) criteria.&#xD;
&#xD;
          -  Requiring treatment with anti-TNFα or anti- IL-17 according to the treatment&#xD;
             recommendations of the French Society of Rheumatology (SFR)&#xD;
&#xD;
          -  patient not previously treated with biotherapy&#xD;
&#xD;
          -  Aged ≥ 18 years&#xD;
&#xD;
          -  Having given free and informed written consent&#xD;
&#xD;
          -  Being affiliated to the center national security system social&#xD;
&#xD;
        For control Subject:&#xD;
&#xD;
          -  Healthy volunteers without diagnosis of spondyloarthritis or any other chronic&#xD;
             disease.&#xD;
&#xD;
          -  Aged ≥ 18 years&#xD;
&#xD;
          -  Having given free and informed written consent&#xD;
&#xD;
          -  Being affiliated with or benefiting from a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons treated with antibiotics, probiotics, prebiotics or any other treatment that&#xD;
             may disrupt the gut microbiota within one month before stool sampling.&#xD;
&#xD;
          -  Association with another chronic pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Européen Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam BENNANI</last_name>
      <phone>04 13 42 83 51</phone>
      <email>m.bennani@hopital-europeen.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline CHARPIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

